Alterome Therapeutics Raises $132M Led by Goldman Sachs for Precision Oncology Initiatives

San Diego, CA, April 3, 2024 (Reuters) -- Alterome Therapeutics announced that it has successfully secured $132 million. Spearheaded by Goldman Sachs Alternatives, this a series B financing brings funding to almost $232M and included notable investors such as Canaan Partners, Driehaus Capital Management, and Digitalis Ventures, along with participation from existing investors. Alterome Therapeutics has stated that the proceeds from this financing will be directed towards "the support and advancement of multiple wholly-owned pipeline programs," including the initiation of clinical development for two precision oncology programs within the next 12 months.

Read full article here.